Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 345

1.

Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.

Baczko I, Liknes D, Yang W, Hamming KC, Searle G, Jaeger K, Husti Z, Juhasz V, Klausz G, Pap R, Saghy L, Varro A, Dolinsky V, Wang S, Rauniyar V, Hall D, Dyck JR, Light PE.

Br J Pharmacol. 2014 Jan;171(1):92-106. doi: 10.1111/bph.12409.

2.

18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.

Du YM, Xia CK, Zhao N, Dong Q, Lei M, Xia JH.

Acta Pharmacol Sin. 2012 Jun;33(6):752-60. doi: 10.1038/aps.2012.22. Epub 2012 May 21.

3.

Effects of the natural flavone trimethylapigenin on cardiac potassium currents.

Liu Y, Xu XH, Liu Z, Du XL, Chen KH, Xin X, Jin ZD, Shen JZ, Hu Y, Li GR, Jin MW.

Biochem Pharmacol. 2012 Aug 15;84(4):498-506. doi: 10.1016/j.bcp.2012.05.002. Epub 2012 May 11.

PMID:
22583923
4.

Piceatannol, a derivative of resveratrol, moderately slows I(Na) inactivation and exerts antiarrhythmic action in ischaemia-reperfused rat hearts.

Chen WP, Hung LM, Hsueh CH, Lai LP, Su MJ.

Br J Pharmacol. 2009 Jun;157(3):381-91. doi: 10.1111/j.1476-5381.2008.00106.x. Epub 2009 Apr 3.

5.

Azithromycin Causes a Novel Proarrhythmic Syndrome.

Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, Luis PB, Hall L, Zhang W, Du L, Milne G, Tucker P, George AL Jr, Campbell CM, Pickett RA, Shaffer CM, Chopra N, Yang T, Knollmann BC, Roden DM, Murray KT.

Circ Arrhythm Electrophysiol. 2017 Apr;10(4). pii: e003560. doi: 10.1161/CIRCEP.115.003560.

PMID:
28408648
6.

Theoretical possibilities for the development of novel antiarrhythmic drugs.

Varró A, Biliczki P, Iost N, Virág L, Hála O, Kovács P, Mátyus P, Papp JG.

Curr Med Chem. 2004 Jan;11(1):1-11. Review.

PMID:
14754422
7.

Inhibition of potassium currents is involved in antiarrhythmic effect of moderate ethanol on atrial fibrillation.

Yang B, Li C, Sun J, Wang X, Liu X, Yang C, Chen L, Zhou J, Hu H.

Toxicol Appl Pharmacol. 2017 May 1;322:89-96. doi: 10.1016/j.taap.2017.03.006. Epub 2017 Mar 9.

PMID:
28284858
8.
9.

Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.

Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath Z, Matschke K, Varro A, Ravens U.

J Cardiovasc Pharmacol. 2013 May;61(5):408-15. doi: 10.1097/FJC.0b013e31828780eb.

PMID:
23364608
10.

Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog.

Qi XY, Diness JG, Brundel BJ, Zhou XB, Naud P, Wu CT, Huang H, Harada M, Aflaki M, Dobrev D, Grunnet M, Nattel S.

Circulation. 2014 Jan 28;129(4):430-40. doi: 10.1161/CIRCULATIONAHA.113.003019. Epub 2013 Nov 4.

11.

Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.

Hashimoto N, Yamashita T, Tsuruzoe N.

J Cardiovasc Pharmacol. 2008 Feb;51(2):162-9. doi: 10.1097/FJC.0b013e31815e854c.

PMID:
18287884
12.

Generation of a constitutive Na+-dependent inward-rectifier current in rat adult atrial myocytes by overexpression of Kir3.4.

Mintert E, Bösche LI, Rinne A, Timpert M, Kienitz MC, Pott L, Bender K.

J Physiol. 2007 Nov 15;585(Pt 1):3-13. Epub 2007 Sep 20.

13.
14.

Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.

Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.

Cardiovasc Res. 2011 Jul 1;91(1):53-61. doi: 10.1093/cvr/cvr044. Epub 2011 Feb 7.

15.

Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.

Comtois P, Sakabe M, Vigmond EJ, Munoz M, Texier A, Shiroshita-Takeshita A, Nattel S.

Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1489-504. doi: 10.1152/ajpheart.01054.2007. Epub 2008 Aug 1.

16.
17.

In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.

Tsujimae K, Murakami S, Kurachi Y.

Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H793-800. Epub 2007 Nov 30.

19.

Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes.

Schumacher-Bass SM, Vesely ED, Zhang L, Ryland KE, McEwen DP, Chan PJ, Frasier CR, McIntyre JC, Shaw RM, Martens JR.

Circ Res. 2014 Mar 14;114(6):982-92. doi: 10.1161/CIRCRESAHA.114.302711. Epub 2014 Feb 7.

20.

Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation.

Hayashi K, Konno T, Tada H, Tani S, Liu L, Fujino N, Nohara A, Hodatsu A, Tsuda T, Tanaka Y, Kawashiri MA, Ino H, Makita N, Yamagishi M.

Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1095-104. doi: 10.1161/CIRCEP.114.002519. Epub 2015 Jun 30.

Supplemental Content

Support Center